WHI
ALNY icon

William Harris Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

William Harris Investors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-3,555
Closed -$228K – 87
2013
Q3 		$228K Buy
+3,555
New +$177K 0.07% 83

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

William Harris Investors's ALNY Position: Q4 2013 in Review

William Harris Investors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2013, closing a stake of 3,555 shares — an estimated $228K sold.

William Harris Investors first reported a position in ALNY in Q3 2013 and held it in 1 quarter. The position peaked at $228K in Q3 2013. 169 funds tracked by Wall St. Rank hold ALNY as of Q4 2013.

  • William Harris Investors reported no remaining Alnylam Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • William Harris Investors sold 3,555 Alnylam Pharmaceuticals shares in Q4 2013, an estimated $228K.
  • William Harris Investors first reported a position in Alnylam Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • William Harris Investors's Alnylam Pharmaceuticals position peaked at $228K in Q3 2013.
  • 169 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2013.

Based on William Harris Investors's 13F filing for Q4 2013, filed 10 Feb 2014.